共 11 条
[2]
Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study
[J].
BRITISH JOURNAL OF DERMATOLOGY,
2021, 184 (05)
:857-870